By InvitationPhase 2

Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.

China30 participantsStarted 2026-05-01

Plain-language summary

A single-arm, single-center clinical trial evaluating efficacy (Phase #)

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Pregnant or lactating women
✕. Previous history of other malignant tumors within the past 5 years, excluding previously cured basal cell carcinoma of the skin and differentiated thyroid carcinoma.
✕. Oral and pharyngeal carcinoma with positive HPV test results
✕. Known hypersensitivity to the investigational drugs pertuzumab or lenvatinib
✕. Currently using and cannot discontinue potent CYP3A4 inhibitors or inducers
✕. Active autoimmune diseases or history of autoimmune diseases
✕. History of immunodeficiency, including HIV-positive status, other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and bone marrow transplantation
✕. History of mental illness or substance abuse

Major Progression Rate (MPR)

Timeframe: up to 6 months

NCT IDNCT07550972

SponsorZhejiang Provincial People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-03-31